(VRNA) – Hot FDA News
-
Verona Pharma (VRNA) Reports Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial
-
Verona Pharma (VRNA) 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy Met its Primary Endpoint
-
-
-
Back to VRNA Stock Lookup